| Primary |
| Product Used For Unknown Indication |
25.7% |
| Drug Use For Unknown Indication |
24.1% |
| Herpes Zoster |
11.5% |
| Prophylaxis |
8.8% |
| Herpes Virus Infection |
3.3% |
| Plasma Cell Myeloma |
3.2% |
| Hypertension |
2.8% |
| Diffuse Large B-cell Lymphoma |
2.7% |
| Antiviral Prophylaxis |
2.3% |
| Hiv Infection |
2.3% |
| Herpes Ophthalmic |
2.2% |
| Acute Lymphocytic Leukaemia |
1.5% |
| Chemotherapy |
1.5% |
| Lymphoma |
1.5% |
| Chronic Lymphocytic Leukaemia |
1.3% |
| Oral Herpes |
1.3% |
| B-cell Lymphoma |
1.0% |
| Bone Marrow Transplant |
1.0% |
| Depression |
1.0% |
| Essential Hypertension |
1.0% |
|
| Renal Failure Acute |
10.2% |
| Overdose |
9.5% |
| Toxic Skin Eruption |
9.5% |
| Vomiting |
8.8% |
| Skin Exfoliation |
7.5% |
| Thrombocytopenia |
7.5% |
| Pyrexia |
5.4% |
| Rash Maculo-papular |
4.8% |
| Renal Failure |
4.8% |
| Hallucination |
4.1% |
| Agranulocytosis |
3.4% |
| Confusional State |
3.4% |
| Neutropenia |
3.4% |
| Somnolence |
3.4% |
| Pancytopenia |
2.7% |
| Toxic Epidermal Necrolysis |
2.7% |
| Urticaria |
2.7% |
| Jaundice |
2.0% |
| Keratitis Herpetic |
2.0% |
| Pruritus |
2.0% |
|
| Secondary |
| Product Used For Unknown Indication |
50.5% |
| Drug Use For Unknown Indication |
10.1% |
| Prophylaxis |
5.9% |
| Herpes Zoster |
4.2% |
| Hypertension |
3.9% |
| Pain |
2.9% |
| Lymphoma |
2.7% |
| Acute Lymphocytic Leukaemia |
2.4% |
| Chronic Lymphocytic Leukaemia |
2.2% |
| Hiv Infection |
2.2% |
| Plasma Cell Myeloma |
2.1% |
| Unevaluable Event |
1.9% |
| Dermatomyositis |
1.5% |
| Infection Prophylaxis |
1.5% |
| Multiple Myeloma |
1.1% |
| Leukaemia |
1.0% |
| Pyrexia |
1.0% |
| Urinary Tract Infection |
1.0% |
| Acute Myeloid Leukaemia |
0.9% |
| B-cell Lymphoma |
0.9% |
|
| Toxic Epidermal Necrolysis |
10.0% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
8.3% |
| Toxic Skin Eruption |
8.3% |
| Rash Maculo-papular |
6.7% |
| Vomiting |
6.7% |
| Neuropathy Peripheral |
5.8% |
| Tumour Lysis Syndrome |
5.8% |
| Disturbance In Attention |
5.0% |
| Neutropenia |
5.0% |
| Skin Exfoliation |
5.0% |
| Cataract |
4.2% |
| Renal Failure Acute |
4.2% |
| Coombs Negative Haemolytic Anaemia |
3.3% |
| Leukopenia |
3.3% |
| Pyrexia |
3.3% |
| Rash |
3.3% |
| Stevens-johnson Syndrome |
3.3% |
| Urticaria |
3.3% |
| Haemolytic Anaemia |
2.5% |
| Thrombocytopenia |
2.5% |
|
| Concomitant |
| Product Used For Unknown Indication |
27.2% |
| Drug Use For Unknown Indication |
20.4% |
| Prophylaxis |
8.1% |
| Hiv Infection |
5.6% |
| Chronic Lymphocytic Leukaemia |
4.9% |
| Plasma Cell Myeloma |
4.7% |
| Diffuse Large B-cell Lymphoma |
3.8% |
| Multiple Myeloma |
3.4% |
| Infection Prophylaxis |
3.2% |
| Acute Lymphocytic Leukaemia |
2.6% |
| B-cell Lymphoma |
2.5% |
| Thrombosis Prophylaxis |
2.2% |
| Hypertension |
2.1% |
| Mantle Cell Lymphoma |
1.9% |
| Acute Myeloid Leukaemia |
1.9% |
| Pain |
1.5% |
| Antiviral Prophylaxis |
1.2% |
| Anxiety |
1.0% |
| Premedication |
1.0% |
| Non-hodgkin's Lymphoma |
0.9% |
|
| Pyrexia |
13.1% |
| Vomiting |
9.7% |
| Thrombocytopenia |
9.1% |
| Septic Shock |
6.7% |
| Renal Failure Acute |
6.0% |
| Toxic Skin Eruption |
6.0% |
| Renal Failure |
5.7% |
| Weight Decreased |
5.0% |
| Pancytopenia |
4.7% |
| Agranulocytosis |
4.0% |
| Lung Disorder |
3.7% |
| Urinary Tract Infection |
3.7% |
| Pneumonia |
3.4% |
| Rash Maculo-papular |
3.4% |
| Death |
3.0% |
| Febrile Bone Marrow Aplasia |
3.0% |
| Pulmonary Embolism |
2.7% |
| Cholestasis |
2.3% |
| General Physical Health Deterioration |
2.3% |
| Hepatocellular Injury |
2.3% |
|
| Interacting |
| Graft Versus Host Disease |
20.0% |
| Hypertension |
13.3% |
| Anaemia |
10.0% |
| Neuralgia |
10.0% |
| Thrombophlebitis |
10.0% |
| Gastrooesophageal Reflux Disease |
6.7% |
| Prophylaxis |
6.7% |
| Anxiety |
3.3% |
| Diuretic Therapy |
3.3% |
| Dyspepsia |
3.3% |
| Gastritis |
3.3% |
| Infection |
3.3% |
| Post Herpetic Neuralgia |
3.3% |
| Respiratory Failure |
3.3% |
|
| Toxic Epidermal Necrolysis |
75.0% |
| Urinary Retention |
25.0% |
|
